Abstract 12P
Background
Mobile health apps are increasingly gaining attention as opportunities to obtain patient-generated health data without asking for self-report or visiting hospital. Since there are few studies regarding the mobile-based activity trackers in breast cancer patients, we decided to evaluate the feasibility of a mobile walking app and a smart band as a tool for collecting physical activity of breast cancer patients.
Methods
Between June 2017 and March 2018, patients who received surgery for breast cancer at Asan Medical Center were enrolled and asked to access two mobile apps on a weekly basis during a six-month period to automatically record their daily physical activity. Compliance rates of the daily collection via a smartphone walking app and a wearable smart band were compared in a within-subject manner. Longitudinal daily collection rates were calculated to examine a drop-out pattern. Finally, we examined factors associated with the compliance of daily collections using multivariate linear regression analysis.
Results
A total of 160 participants were analyzed, and they are asked to follow an instruction to access the apps at least once a week via their smartphones. Despite the fact that both smartphone app and the smart band showed more than 50% of compliance rate during the six-month follow-up period, smartphone walking app demonstrated higher overall compliance rate (88%) than a smart band (52%). The median value of individual compliance rate is 91% for the walking app and 55% for a smart band. Women having other diseases, an anti-hormonal therapy or a targeted therapy show a higher compliance rate to smartphone walking app, and young women show a higher rate to the app than older women. However, there was no association between any of the patient characteristics and a compliance rate to the smart band.
Conclusions
Smartphone apps or smart bands are feasible tools to collect daily physical activity data for in breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yungil Shin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract